Clinical trial · Interventional
A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled ZT-111 in Patients With Metastatic Prostate Cancer
NCT06201741CI-TRIAL-00073286unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to evaluate the safety, biodistribution, radiation dosimetry and tumor uptake of the \[131I\]/\[18F\]/\[68Ga\]ZT-111 in patients with PSMA positive metastatic prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Specific Membrane Antigen Positive Metastatic Prostate Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [131I]/[18F]/[68Ga]ZT-111 | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- [131I]/[18F]/[68Ga]ZT-111
- description
- \[131I\]/\[18F\]/\[68Ga\]ZT-111, single dose
- interventionNames
- Radiation: [131I]/[18F]/[68Ga]ZT-111
Primary outcomes (1)
- measure
- Dosimetry
- timeFrame
- About 24hours from time of injection
- description
- Whole body and organ uptake activity
Secondary outcomes (1)
- measure
- Incidence and severity of adverse events
- timeFrame
- From administration of [131I]/[18F]/[68Ga]ZT-111 until 1 week after injection
- description
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age between 18 and 65 years old. 2. Histologically or cytologically confirmed prostate adenocarcinoma with documented history of ≥1 metastatic lesions indicated by imaging. 3. Informed consent must be obtained in writing from the subject, their legally authorized representative, or caregiver. 4. Willing and able to comply with all aspects of this study. Exclusion Criteria: 1. Severe hepatic or renal impairment. 2. History of major surgery within the last month. 3. Participation in another concurrent clinical trial.
References
Publications (0)
Data not yet available
No reference posted for this study.